Crestor vs Losartan: Cost, Access, and Clinical Evidence Compared

Why These Two Drugs Are Compared (and Why They Shouldn't Be Swapped)

Rosuvastatin and losartan treat different pathologies within the cardiometabolic spectrum. Rosuvastatin targets LDL cholesterol and systemic inflammation. Losartan targets blood pressure through the renin-angiotensin-aldosterone system (RAAS). A patient cannot replace one with the other; each addresses a distinct risk factor for heart attack and stroke.

The comparison comes up because prescribers frequently write both on the same prescription pad during the same visit, and patients want to know which one matters more for their wallet and their arteries. The 2018 ACC/AHA cholesterol guidelines recommend moderate-to-high-intensity statin therapy for adults with clinical atherosclerotic cardiovascular disease (ASCVD), and the 2017 ACC/AHA hypertension guideline recommends first-line antihypertensive therapy (including ARBs) for adults with blood pressure at or above 130/80 mmHg. Both drugs may be prescribed concurrently. Stopping one to save money on the other is a clinical error, not a cost-saving strategy.

The 2019 ACC/AHA Primary Prevention guideline notes that adults aged 40 to 75 with a 10-year ASCVD risk of 7.5% or higher should be on a statin, irrespective of blood-pressure treatment status [3]. This means the question is rarely "rosuvastatin or losartan" and more often "which combination keeps out-of-pocket spend lowest."

Clinical Evidence: JUPITER and LIFE

The JUPITER trial (N=17,802), published in the New England Journal of Medicine in 2008, randomized apparently healthy adults with LDL cholesterol below 130 mg/dL but high-sensitivity C-reactive protein (hsCRP) of 2.0 mg/L or higher to rosuvastatin 20 mg daily or placebo. The trial was stopped early at a median of 1.9 years because the treatment arm showed a 44% relative reduction in the primary composite endpoint of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or confirmed cardiovascular death (HR 0.56; 95% CI 0.46 to 0.69; P<0.00001) [1].

The LIFE trial (N=9,193), published in The Lancet in 2002, compared losartan-based therapy to atenolol-based therapy in patients with essential hypertension and electrocardiographic left ventricular hypertrophy. Over a mean follow-up of 4.8 years, the losartan group showed a 13% relative risk reduction in the primary composite endpoint of cardiovascular death, stroke, or myocardial infarction (adjusted HR 0.87; 95% CI 0.77 to 0.98; P=0.021) [2]. The stroke reduction was especially pronounced: 25% lower risk with losartan versus atenolol.

No head-to-head trial has directly compared rosuvastatin to losartan. Such a trial would not be clinically meaningful because these drugs target different physiological pathways. The comparison that matters is whether each drug, within its own class, delivers strong enough evidence to justify its place in a multi-drug cardiometabolic regimen. Both do.

Dr. Paul Ridker, the lead investigator of JUPITER, stated: "These data suggest that people who have low cholesterol but are otherwise at risk due to inflammation may benefit substantially from statin therapy" [1]. This finding expanded the population eligible for rosuvastatin beyond traditional lipid thresholds.

Cost Comparison: Generic Pricing in 2026

Both drugs are available as affordable generics, making cost a secondary concern for most patients with any form of prescription coverage. Here is what patients can expect to pay.

Rosuvastatin (generic Crestor): The brand-name Crestor launched at roughly $260 per month. After patent expiration in 2016, generic rosuvastatin entered the market and crashed the price. In 2026, a 30-day supply of rosuvastatin 10 mg costs approximately $4 to $15 at major chain pharmacies using discount programs such as GoodRx, RxSaver, or Amazon Pharmacy. The FDA Orange Book lists multiple AB-rated generic manufacturers, which sustains competitive pricing.

Losartan (generic Cozaar): Generic losartan has been available since 2010. A 30-day supply of losartan 50 mg typically costs $3 to $12 at retail pharmacies. Losartan 100 mg runs slightly higher, generally $5 to $18. Both strengths are among the lowest-cost generics dispensed in U.S. pharmacies. The CDC National Center for Health Statistics has reported that ARBs and statins together rank among the top 10 most-prescribed drug classes in the United States.

For patients paying cash without insurance, the combined monthly cost of both drugs can stay below $25. Many $4 generic lists at Walmart, Costco, and regional pharmacies carry both rosuvastatin and losartan.

Insurance Coverage and Formulary Placement

Both rosuvastatin and losartan sit on Tier 1 (preferred generic) of the vast majority of commercial, Medicare Part D, and Medicaid formularies. Tier 1 placement means the lowest possible copay, often $0 to $10 per 30-day fill.

A 2023 analysis from the Centers for Medicare & Medicaid Services found that rosuvastatin was covered on 98% of Medicare Part D standalone plans without prior authorization. Losartan appeared on 99% of Part D formularies, also without prior authorization. Neither drug typically requires step therapy.

For patients on high-deductible health plans (HDHPs), both generics qualify for pre-deductible coverage under IRS Notice 2019-45, which allows HDHPs to cover certain preventive medications (including statins and antihypertensives for heart disease prevention) with a $0 copay before the deductible is met [4]. This 2019 IRS expansion specifically listed "statins" and "blood pressure medications" as preventive drug categories. Patients should confirm with their plan, but the regulatory pathway exists.

The Inflation Reduction Act's $2,000 annual out-of-pocket cap for Medicare Part D, which took full effect in 2025, further insulates Medicare beneficiaries from combined costs even if they take both drugs alongside other prescriptions. For dual-eligible (Medicare + Medicaid) patients, copays for generics max out at $4.50 per fill in 2026.

Side-Effect Profiles: What Patients Weigh Against Cost

Side effects influence adherence, and adherence drives long-term cost-effectiveness. A cheaper drug means nothing if a patient stops taking it.

Rosuvastatin side effects include myalgia (muscle pain) in approximately 5% to 10% of patients exposed to statins as a class, though true statin-attributable muscle symptoms (confirmed by rechallenge or dechallenge) are lower, closer to 1% to 3% per the 2018 AHA Scientific Statement on statin safety [5]. Rare but serious risks include rhabdomyolysis (incidence roughly 1.6 per 100,000 person-years), hepatotoxicity, and new-onset type 2 diabetes. The JUPITER trial itself observed a small increase in physician-reported diabetes (3.0% vs 2.4%, P=0.01) in the rosuvastatin arm [1]. Rosuvastatin 40 mg also carries a dose-dependent risk of proteinuria, which is why 40 mg is reserved for patients not reaching LDL goals on lower doses.

Losartan is generally well tolerated. The most commonly reported side effects in clinical trials include dizziness (2.4%), upper respiratory infection, and nasal congestion. ARBs as a class are known for a lower incidence of dry cough compared to ACE inhibitors, which is one reason clinicians switch ACE-intolerant patients to losartan. Hyperkalemia is a potential risk, particularly in patients with chronic kidney disease or those taking potassium-sparing diuretics. The 2020 Endocrine Society clinical practice guideline recommends monitoring serum potassium within 2 to 4 weeks of initiating ARB therapy in patients with eGFR below 45 mL/min/1.73 m².

From a tolerability standpoint, losartan tends to produce fewer complaints that cause discontinuation. Statin intolerance (real or perceived) is a more common clinical conversation, though switching among statins or dose-reducing often resolves the issue.

Access Beyond Price: Availability, Telehealth, and Mail Order

Availability is rarely a barrier for either drug. Both are manufactured by dozens of generic companies and stocked by every retail pharmacy in the United States.

Mail-order pharmacies (Express Scripts, CVS Caremark, Optum Rx, Amazon Pharmacy, Mark Cuban's Cost Plus Drugs) typically offer 90-day supplies at a discount. A 90-day supply of rosuvastatin 10 mg through Cost Plus Drugs runs around $5 to $7 total. Losartan 50 mg for 90 days costs roughly $4 to $6 at the same outlet. These prices are often lower than insurance copays, which creates an unusual situation where patients save money by not using their insurance and paying the cash price instead.

Telehealth prescribing for both drugs is straightforward. Statins and ARBs do not carry DEA scheduling restrictions. Any licensed prescriber can write these prescriptions via a synchronous telehealth visit in all 50 states, and renewals can proceed asynchronously in states that allow it. At HealthRX, clinicians can evaluate cardiometabolic labs (lipid panel, metabolic panel, hsCRP) and prescribe both drugs during a single telehealth consultation.

Patients in rural areas or pharmacy deserts face no meaningful access gap for either drug because mail-order delivery removes geography from the equation. The USDA Economic Research Service has documented that roughly 2.3 million Americans live more than 10 miles from the nearest pharmacy. For these patients, 90-day mail-order supply is the practical standard.

Who Needs Rosuvastatin, Who Needs Losartan, and Who Needs Both

The decision tree is straightforward. If a patient's primary risk factor is elevated LDL cholesterol or elevated hsCRP with intermediate-to-high ASCVD risk, rosuvastatin is indicated. If the primary risk factor is hypertension, losartan (or another first-line antihypertensive) is indicated.

Patients with metabolic syndrome, type 2 diabetes, or established ASCVD frequently need both. The 2022 AHA/ACC/HFSA guideline for the management of heart failure recommends RAAS inhibition (including ARBs like losartan) as foundational therapy in heart failure with reduced ejection fraction, while statins are recommended for patients with heart failure of ischemic etiology [6].

Specific populations that commonly receive both drugs concurrently:

• Adults over 50 with type 2 diabetes and LDL above 70 mg/dL
• Patients with chronic kidney disease stages 1 to 3 (losartan provides renal protection via RAAS blockade; rosuvastatin addresses the accelerated atherosclerosis of CKD)
• Post-MI patients with hypertension
• Adults with metabolic syndrome (abdominal obesity, triglycerides above 150 mg/dL, blood pressure at or above 130/85 mmHg, fasting glucose above 100 mg/dL, and HDL below 40 mg/dL in men or below 50 mg/dL in women)

A 2021 retrospective cohort study published in the Journal of the American Heart Association found that concurrent statin-ARB use in patients with hypertension and dyslipidemia was associated with a 21% lower hazard of major adverse cardiovascular events compared to statin use alone over a median follow-up of 5.2 years (HR 0.79; 95% CI 0.71 to 0.88) [7]. This underscores that the two drugs are additive, not redundant.

Dose Ranges and Practical Prescribing

Rosuvastatin is available in 5 mg, 10 mg, 20 mg, and 40 mg tablets. The ACC/AHA guidelines define high-intensity statin therapy as rosuvastatin 20 to 40 mg daily (expected LDL reduction of 50% or more) and moderate-intensity as rosuvastatin 5 to 10 mg daily (expected LDL reduction of 30% to 49%) [3]. Most patients start at 10 mg or 20 mg. The 40 mg dose is not first-line and requires renal function assessment before initiation.

Losartan is available in 25 mg, 50 mg, and 100 mg tablets. Starting dose for hypertension is typically 50 mg once daily, titrated to 100 mg once daily if needed. For diabetic nephropathy, the target dose is 100 mg daily per the FDA-approved labeling. Losartan is also available as a fixed-dose combination with hydrochlorothiazide (losartan/HCTZ 50/12.5 mg and 100/25 mg), though the combination product costs slightly more than the individual components.

Both drugs are taken once daily, which simplifies adherence for patients on multi-drug regimens. Neither requires administration with food, though rosuvastatin absorption is not affected by meal timing, and losartan can be taken at any time of day.

Drug Interactions Worth Knowing

Rosuvastatin interacts with cyclosporine (contraindicated in combination), gemfibrozil (increases rosuvastatin exposure 2-fold), and certain protease inhibitors used in HIV therapy. Rosuvastatin is not extensively metabolized by CYP3A4, which gives it fewer interactions than atorvastatin or simvastatin. The FDA prescribing information recommends a maximum rosuvastatin dose of 5 mg when co-administered with cyclosporine.

Losartan is metabolized by CYP2C9 and CYP3A4 to its active metabolite E-3174, which is 10 to 40 times more potent as an angiotensin II receptor antagonist than the parent compound. Drugs that inhibit CYP2C9 (fluconazole, amiodarone) may reduce conversion to the active metabolite and diminish antihypertensive efficacy. Concurrent use of losartan with potassium supplements, potassium-sparing diuretics, or other RAAS inhibitors increases the risk of hyperkalemia.

Taking rosuvastatin and losartan together does not produce a clinically significant pharmacokinetic interaction, and the combination is widely prescribed without dose adjustments.

Switching Between These Drugs Is a Category Error

Patients sometimes ask whether they can stop one drug and keep the other to reduce pill burden or cost. This is like asking whether you can skip the oil change because you already rotated the tires. These drugs serve different mechanical functions.

A patient on rosuvastatin 20 mg for dyslipidemia who also develops hypertension needs losartan added, not substituted. A patient on losartan 100 mg for blood pressure who then gets a lipid panel showing LDL of 160 mg/dL needs rosuvastatin added. No guideline from the ACC, AHA, or Endocrine Society supports discontinuing one of these drugs in favor of the other.

The only scenario where a patient might take one but not the other is when they have isolated hyperlipidemia without hypertension (rosuvastatin alone) or isolated hypertension without dyslipidemia (losartan alone). Even then, prescribers reassess annually as metabolic risk factors evolve with aging.